The Greek pharmaceutical industry has reached its limits due to a number of “unreasonable” burdens imposed by the government during the crisis, Greek pharma chief Olympios Papadimitriou told EURACTIV.com in an interview. The sustainability of pharma companies is at stake, threatening 86,000 jobs, he said.
A number of member states want the European Commission’s competences in health and pharma policy to be upgraded in order to face more effectively the rising challenges in the field, Greek health minister Andreas Ksanthos told EURACTIV.com in an interview.
The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.
The next European Commission should focus on the bloc’s role in the global context of innovation, as China is “decisive” about creating a reliable framework for intellectual property and connecting biotech start-ups and digital companies, EFPIA’s President Stefan Oschmann told EURACTIV.com in an interview.
The adoption of an outcome-based approach regarding the remuneration of medicines should take into account the entire chain, including the distributors, René Jenny, President of the European Healthcare Distribution Association (GIRP), told EURACTIV.com.
Experts are asking for a more collaborative approach in EU healthcare and greater involvement of the European Commission in order to face rising challenges and put patients at the core of decision-making.
The Novartis scandal in Greece exists and the people responsible for it should be dealt with quickly in order to avoid a “social eruption”, Greek business leader Konstantinos Michalos told EURACTIV.com in an interview.
The Greek parliament decided on 21 February to establish a special committee that will investigate the role of politicians in the alleged Novartis scandal, a case that analysts claim will shake up the country’s political system.